Table of Contents
Table of Contents 2
List of Tables 10
List of Figures 17
Introduction 18
Global Markets Direct Report Coverage 18
Prostate Cancer Overview 19
Therapeutics Development 20
An Overview of Pipeline Products for Prostate Cancer 20
Prostate Cancer Therapeutics under Development by Companies 22
Prostate Cancer Therapeutics under Investigation by Universities/Institutes 37
Late Stage Products 49
Comparative Analysis 49
Mid Clinical Stage Products 50
Comparative Analysis 50
Early Clinical Stage Products 51
Comparative Analysis 51
Discovery and Pre-Clinical Stage Products 52
Comparative Analysis 52
Prostate Cancer Therapeutics – Products under Development by Companies 53
Prostate Cancer Therapeutics – Products under Investigation by Universities/Institutes 73
Companies Involved in Prostate Cancer Therapeutics Development 104
Bristol-Myers Squibb Company 104
Genzyme Corporation 105
Johnson & Johnson 106
Boehringer Ingelheim GmbH 107
Abbott Laboratories 108
Amgen Inc. 109
Sanofi-Aventis 110
Adherex Technologies Inc. 111
AstraZeneca PLC 112
Eli Lilly and Company 113
Viralytics Ltd. 114
Bioniche Life Sciences, Inc. 115
Genentech, Inc. 116
Nektar Therapeutics 117
Inovio Biomedical Corporation 118
Bavarian Nordic A/S 119
Isis Pharmaceuticals, Inc. 120
Daiichi Sankyo Company, Ltd 121
Merck & Co., Inc. 122
Oxford BioMedica plc 123
Micromet, Inc. 124
Infinity Pharmaceuticals, Inc. 125
Generex Biotechnology Corporation 126
Takeda Pharmaceutical Company Limited 127
Albany Molecular Research, Inc. 128
Light Sciences Oncology, Inc. 129
Ipsen S.A. 130
Panacea Pharmaceuticals, Inc. 131
Bio-Path Holdings, Inc. 132
Ambrilia Biopharma Inc. 133
ZIOPHARM Oncology, Inc. 134
Millennium Pharmaceuticals, Inc. 135
Novartis AG 136
Aphios Corporation 137
ImClone Systems Incorporated 138
Astellas Pharma Inc. 139
Cephalon, Inc. 140
Eisai Co., Ltd. 141
Genta Incorporated 142
GTx, Inc. 143
Nippon Shinyaku Co., Ltd. 144
Ono Pharmaceutical Co., Ltd. 145
Orion Corporation 146
Pfizer Inc. 147
SuperGen, Inc. 148
Taiho Pharmaceutical Co., Ltd. 149
Teva Pharmaceutical Industries Limited 150
Samaritan Pharmaceuticals, Inc. 202
Threshold Pharmaceuticals, Inc. 203
Synta Pharmaceuticals Corp. 204
Sareum Holdings plc 205
Oasmia Pharmaceutical AB 206
Protox Therapeutics Inc. 207
RXi Pharmaceuticals Corporation 208
Hybrigenics S.A. 209
Rexahn Pharmaceuticals, Inc. 210
Emiliem, Inc. 211
Oryzon 212
Debiopharm Group 213
Antisense Pharma GmbH 214
Avanti Therapeutics 215
Chipscreen Biosciences Ltd 216
Camurus AB 217
Immupharma Plc 218
Actinium Pharmaceuticals, Inc. 219
Med Discovery SA 220
ERYtech Pharma 221
Pro-Cure Therapeutics Limited 222
Vaxon Biotech 223
Advantagene, Inc. 224
CureVac GmbH 225
Alethia Biotherapeutics Inc. 226
GenSpera, Inc. 227
Cellectis S.A. 228
Center of Molecular Immunology 229
Ascenta Therapeutics, Inc. 230
Adamis Pharmaceuticals Corporation 270
Tigris Pharmaceuticals, Inc. 271
Cylene Pharmaceuticals, Inc. 272
WntResearch AB 273
Viventia Biotechnologies Inc. 274
IRX Therapeutics, Inc. 275
TRACON Pharmaceuticals, Inc. 276
Archer Biosciences, Inc 277
Nometics Inc. 278
Ferring Pharmaceuticals, Inc. 279
Advanced Cancer Therapeutics 280
Viamet Pharmaceuticals, Inc. 281
EUSA Pharma, Inc. 282
Kotinos Pharmaceuticals, Inc. 283
Cellceutix Pharmaceuticals, Inc. 284
Acuvax Ltd 285
Targa Therapeutics Corp. 286
Aragon Pharmaceuticals, Inc. 287
Vakzine Projekt Management GmbH 288
Medical Marketing International Group plc 289
Ausio Pharmaceuticals, LLC 290
Steba Laboratories Ltd. 291
Errant Gene Therapeutics, LLC 292
Polaris Group 293
ImQuest Life Sciences 294
CytoVac A/S 295
Prostate Cancer – Therapeutics Assessment 296
Assessment by Monotherapy Products 296
Assessment by Combination Products 297
Assessment by Route of Administration 298
Assessment by Molecule Type 301
Drug Profiles 304
Yervoy - Drug Profile 304
Firmagon - Drug Profile 306
TAK-700 - Drug Profile 307
TV-1011 - Drug Profile 309
Zytiga - Drug Profile 311
TASQ - Drug Profile 312
MDV3100 - Drug Profile 314
Cabozantinib - Drug Profile 316
Leuprolide 22.5 - Drug Profile 318
Leuprolide 7.5 - Drug Profile 320
Prostvac - Drug Profile 321
DCVax-Prostate - Drug Profile 322
Docetaxel + Prednisone + Atrasentan - Drug Profile 323
Dutasteride - Drug Profile 325
Antiandrogen Therapy + LHRH agonist - Drug Profile 326
Androgen Blockade Therapy + Zoledronic Acid - Drug Profile 328
Gemcitabine + Cisplatin + Bevacizumab - Drug Profile 329
Bicalutamide + Goserelin + Radiation Therapy - Drug Profile 330
Radiation Therapy + Bicalutamide - Drug Profile 331
Radiation Therapy + Androgen Deprivation Therapy - Drug Profile 333
Radiation Therapy + Leuprolide Acetate - Drug Profile 335
Hormone Therapy + Docetaxel + Estramustine - Drug Profile 337
Hormone Therapy - Drug Profile 340
Androgen suppression + Zoledronate - Drug Profile 342
Androgen suppression + Docetaxel + Prednisolone - Drug Profile 343
Androgen suppression + Celecoxib - Drug Profile 345
Androgen suppression + Zoledronate + Celecoxib - Drug Profile 346
Androgen suppression + Zoledronate + Docetaxel + Prednisolone - Drug Profile 348
Doxorubicin Hydrochloride + Estramustine Phosphate Sodium + Ketoconazole + Vinblastine - Drug Profile 350
Docetaxel + Prednisone - Drug Profile 352
Doxorubicin Hydrochloride + Strontium chloride Sr 89 - Drug Profile 353
Docetaxel + Prednisone + Doxorubicin Hydrochloride - Drug Profile 355
Radiation Therapy + Casodex - Drug Profile 357
Dutasteride - Drug Profile 359
AdV-tk + Valacyclovir + Radiation Therapy - Drug Profile 360
Lutrate Depot - Drug Profile 362
Lutrate Depot - Drug Profile 364
Zibotentan + Taxotere - Drug Profile 366
TV-1011 + Docetaxel - Drug Profile 368
Asentar + Taxotere - Drug Profile 370
Eligard + Taxotere - Drug Profile 372
Sprycel + Docetaxel + Prednisone - Drug Profile 373
Zoledronic Acid - Drug Profile 374
Rapamune - Drug Profile 375
Ciprofloxacine - Drug Profile 376
Bevacizumab + Docetaxel + Prednisone - Drug Profile 377
Docetaxel + Androgen Deprivation Therapy - Drug Profile 379
Ipilimumab + Radiation Therapy - Drug Profile 381
Bicalutamide + Goserelin + Radiation Therapy - Drug Profile 382
Docetaxel + Prednisone + Vatalanib - Drug Profile 384
Thalidomide + Leuprolide Acetate + Goserelin - Drug Profile 386
Bicalutamide + Goserelin - Drug Profile 388
Docetaxel + Prednisone - Drug Profile 390
Docetaxel + Risedronate + Prednisone - Drug Profile 391
Aflibercept + Taxotere + Prednisone - Drug Profile 393
Bicalutamide - Drug Profile 394
Bicalutamide + Goserelin Acetate - Drug Profile 395
Zoladex + Eulexin + Radiation Therapy - Drug Profile 396
GM2-KLH + QS21 - Drug Profile 398
Docetaxel + Hormonal Therapy - Drug Profile 400
Dexamethasone - Drug Profile 401
Ad5-yCD/mutTKSR39rep-ADP + Radiation Therapy - Drug Profile 402
Eulexin + Zoladex - Drug Profile 403
Eulexin + Lupron - Drug Profile 404
AntiAndrogen Therapy + Goserelin + Docetaxel - Drug Profile 405
celecoxib + docetaxel + prednisolone + zoledronic acid - Drug Profile 406
Docetaxel + Antiandrogen Therapy - Drug Profile 408
Bevacizumab + Carboplatin + Paclitaxel - Drug Profile 410
Triptorelin + Flutamide + Radiation Therapy - Drug Profile 412
Mitoxantrone + Prednisone + Clodronate - Drug Profile 414
Flutamide + Goserelin + Radiation therpahy - Drug Profile 416
Flutamide + Goserelin + Leuprolide Acetate + Radiation Therapy - Drug Profile 418
Estramustine + Docetaxel - Drug Profile 420
Meloxicam - Drug Profile 421
Goserelin + Radiation Therapy - Drug Profile 422
Dexamethasone - Drug Profile 423
Docetaxel + Prednisone - Drug Profile 424
Dutasteride - Drug Profile 425
Flutamide + Goserelin Acetate + Low-LET Photon Therapy - Drug Profile 426
Gemcitabine + Cisplatin - Drug Profile 428
Ketoconazole + Hydrocortisone - Drug Profile 430
Mitoxantrone + Prednisone - Drug Profile 432
TAK-700 + Prednisone - Drug Profile 434
Docetaxel - Drug Profile 435
Zaltrap - Drug Profile 436
Docetaxel - Drug Profile 438
ProstAtak - Drug Profile 439
Peptide Vaccine + Estramustine - Drug Profile 441
PROSTVAC + GM-CSF - Drug Profile 442
Docetaxel + Estramustine - Drug Profile 444
CB7630 + Prednisone - Drug Profile 445
Prostate Cancer Therapeutics – Drug Profile Updates 447
Prostate Cancer Therapeutics – Discontinued Products 465
Prostate Cancer Therapeutics - Dormant Products 473
Prostate Cancer – Product Development Milestones 505
Featured News & Press Releases 505
Appendix 515
Methodology 515
Coverage 515
Secondary Research 515
Primary Research 515
Expert Panel Validation 516
Contact Us 516
Disclaimer 516
List of Tables
Number of Products Under Development for Prostate Cancer, H1 2012 26
Products under Development for Prostate Cancer – Comparative Analysis, H1 2012 27
Number of Products under Development by Companies, H1 2012 29
Number of Products under Development by Companies, H1 2012 (Contd..1) 30
Number of Products under Development by Companies, H1 2012 (Contd..2) 31
Number of Products under Development by Companies, H1 2012 (Contd..3) 32
Number of Products under Development by Companies, H1 2012 (Contd..4) 33
Number of Products under Development by Companies, H1 2012 (Contd..5) 34
Number of Products under Development by Companies, H1 2012 (Contd..6) 35
Number of Products under Development by Companies, H1 2012 (Contd..7) 36
Number of Products under Development by Companies, H1 2012 (Contd..8) 37
Number of Products under Development by Companies, H1 2012 (Contd..9) 38
Number of Products under Development by Companies, H1 2012 (Contd..10) 39
Number of Products under Development by Companies, H1 2012 (Contd..11) 40
Number of Products under Development by Companies, H1 2012 (Contd..12) 41
Number of Products under Development by Companies, H1 2012 (Contd..13) 42
Number of Products under Investigation by Universities/Institutes, H1 2012 44
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 45
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 46
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 47
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 48
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 49
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 50
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 51
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 52
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 53
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 54
Comparative Analysis by Late Stage Development, H1 2012 55
Comparative Analysis by Mid Clinical Stage Development, H1 2012 56
Comparative Analysis by Early Clinical Stage Development, H1 2012 57
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 58
Products under Development by Companies, H1 2012 59
Products under Development by Companies, H1 2012 (Contd..1) 60
Products under Development by Companies, H1 2012 (Contd..2) 61
Products under Development by Companies, H1 2012 (Contd..3) 62
Products under Development by Companies, H1 2012 (Contd..4) 63
Products under Development by Companies, H1 2012 (Contd..5) 64
Products under Development by Companies, H1 2012 (Contd..6) 65
Products under Development by Companies, H1 2012 (Contd..7) 66
Products under Development by Companies, H1 2012 (Contd..8) 67
Products under Development by Companies, H1 2012 (Contd..9) 68
Products under Development by Companies, H1 2012 (Contd..10) 69
Products under Development by Companies, H1 2012 (Contd..11) 70
Products under Development by Companies, H1 2012 (Contd..12) 71
Products under Development by Companies, H1 2012 (Contd..13) 72
Products under Development by Companies, H1 2012 (Contd..14) 73
Products under Development by Companies, H1 2012 (Contd..15) 74
Products under Development by Companies, H1 2012 (Contd..16) 75
Products under Development by Companies, H1 2012 (Contd..17) 76
Products under Development by Companies, H1 2012 (Contd..18) 77
Products under Development by Companies, H1 2012 (Contd..19) 78
Products under Investigation by Universities/Institutes, H1 2012 79
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1) 80
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2) 81
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3) 82
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4) 83
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5) 84
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6) 85
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7) 86
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8) 87
Products under Investigation by Universities/Institutes, H1 2012 (Contd..9) 88
Products under Investigation by Universities/Institutes, H1 2012 (Contd..10) 89
Products under Investigation by Universities/Institutes, H1 2012 (Contd..11) 90
Products under Investigation by Universities/Institutes, H1 2012 (Contd..12) 91
Products under Investigation by Universities/Institutes, H1 2012 (Contd..13) 92
Products under Investigation by Universities/Institutes, H1 2012 (Contd..14) 93
Products under Investigation by Universities/Institutes, H1 2012 (Contd..15) 94
Products under Investigation by Universities/Institutes, H1 2012 (Contd..16) 95
Products under Investigation by Universities/Institutes, H1 2012 (Contd..17) 96
Products under Investigation by Universities/Institutes, H1 2012 (Contd..18) 97
Products under Investigation by Universities/Institutes, H1 2012 (Contd..19) 98
Products under Investigation by Universities/Institutes, H1 2012 (Contd..20) 99
Products under Investigation by Universities/Institutes, H1 2012 (Contd..21) 100
Products under Investigation by Universities/Institutes, H1 2012 (Contd..22) 101
Products under Investigation by Universities/Institutes, H1 2012 (Contd..23) 102
Products under Investigation by Universities/Institutes, H1 2012 (Contd..24) 103
Products under Investigation by Universities/Institutes, H1 2012 (Contd..25) 104
Products under Investigation by Universities/Institutes, H1 2012 (Contd..26) 105
Products under Investigation by Universities/Institutes, H1 2012 (Contd..27) 106
Products under Investigation by Universities/Institutes, H1 2012 (Contd..28) 107
Products under Investigation by Universities/Institutes, H1 2012 (Contd..29) 108
Products under Investigation by Universities/Institutes, H1 2012 (Contd..30) 109
Bristol-Myers Squibb Company, H1 2012 110
Genzyme Corporation, H1 2012 111
Johnson & Johnson, H1 2012 112
Boehringer Ingelheim GmbH, H1 2012 113
Abbott Laboratories, H1 2012 114
Amgen Inc., H1 2012 115
Sanofi-Aventis, H1 2012 116
Adherex Technologies Inc., H1 2012 117
AstraZeneca PLC, H1 2012 118
Eli Lilly and Company, H1 2012 119
Viralytics Ltd., H1 2012 120
Bioniche Life Sciences, Inc., H1 2012 121
Genentech, Inc., H1 2012 122
Nektar Therapeutics, H1 2012 123
Inovio Biomedical Corporation, H1 2012 124
Bavarian Nordic A/S, H1 2012 125
Isis Pharmaceuticals, Inc., H1 2012 126
Daiichi Sankyo Company, Ltd, H1 2012 127
Merck & Co., Inc., H1 2012 128
Oxford BioMedica plc, H1 2012 129
Micromet, Inc., H1 2012 130
Infinity Pharmaceuticals, Inc., H1 2012 131
Generex Biotechnology Corporation, H1 2012 132
Takeda Pharmaceutical Company Limited, H1 2012 133
Albany Molecular Research, Inc., H1 2012 134
Light Sciences Oncology, Inc., H1 2012 135
Ipsen S.A., H1 2012 136
Panacea Pharmaceuticals, Inc., H1 2012 137
Bio-Path Holdings, Inc., H1 2012 138
Ambrilia Biopharma Inc., H1 2012 139
ZIOPHARM Oncology, Inc., H1 2012 140
Millennium Pharmaceuticals, Inc., H1 2012 141
Novartis AG, H1 2012 142
Aphios Corporation, H1 2012 143
ImClone Systems Incorporated, H1 2012 144
Astellas Pharma Inc., H1 2012 145
Cephalon, Inc., H1 2012 146
Eisai Co., Ltd., H1 2012 147
Genta Incorporated, H1 2012 148
GTx, Inc., H1 2012 149
Nippon Shinyaku Co., Ltd., H1 2012 150
Ono Pharmaceutical Co., Ltd., H1 2012 151
Orion Corporation, H1 2012 152
Pfizer Inc., H1 2012 153
SuperGen, Inc., H1 2012 154
Taiho Pharmaceutical Co., Ltd., H1 2012 155
Teva Pharmaceutical Industries Limited, H1 2012 156
Progenics Pharmaceuticals, Inc., H1 2012 157
Santaris Pharma A/S, H1 2012 158
Exelixis, Inc., H1 2012 159
Aduro BioTech, H1 2012 160
Menarini Group, H1 2012 161
Alfacell Corporation, H1 2012 162
Celgene Corporation, H1 2012 163
Bayer AG, H1 2012 164
Incyte Corporation, H1 2012 165
Geron Corporation, H1 2012 166
MannKind Corporation, H1 2012 167
Merck KGaA, H1 2012 168
Advaxis, Inc., H1 2012 169
Alchemia Limited, H1 2012 170
Addex Pharmaceuticals, H1 2012 171
Genesis Research and Development Corporation Ltd., H1 2012 172
GW Pharmaceuticals plc, H1 2012 173
Hollis-Eden Pharmaceuticals, Inc., H1 2012 174
Celldex Therapeutics, Inc., H1 2012 175
Anavex Life Sciences Corp., H1 2012 176
Cougar Biotechnology, Inc., H1 2012 177
ValiRx Plc, H1 2012 178
Active Biotech AB, H1 2012 179
AEterna Zentaris Inc., H1 2012 180
Antisense Therapeutics Limited, H1 2012 181
Lorus Therapeutics Inc, H1 2012 182
Molecular Insight Pharmaceuticals, Inc., H1 2012 183
Neuren Pharmaceuticals Limited, H1 2012 184
Northwest Biotherapeutics, Inc., H1 2012 185
Cleveland BioLabs, Inc., H1 2012 186
Oncolytics Biotech Inc., H1 2012 187
Oncothyreon Inc, H1 2012 188
OncoVista Innovative Therapies, Inc., H1 2012 189
Compugen Ltd., H1 2012 190
Osta Biotechnologies Inc., H1 2012 191
Patrys Limited, H1 2012 192
Peregrine Pharmaceuticals, Inc., H1 2012 193
Medivation, Inc., H1 2012 194
ADVENTRX Pharmaceuticals, H1 2012 195
Telik, Inc., H1 2012 196
Transcept Pharmaceuticals, Inc., H1 2012 197
Soligenix, Inc., H1 2012 198
Poniard Pharmaceuticals, Inc., H1 2012 199
Regeneron Pharmaceuticals, Inc., H1 2012 200
List of Figures
Number of Products under Development for Prostate Cancer, H1 2012 26
Products under Development for Prostate Cancer – Comparative Analysis, H1 2012 27
Products under Development by Companies, H1 2012 28
Products under Investigation by Universities/Institutes, H1 2012 43
Late Stage Products, H1 2012 55
Mid Clinical Stage Products, H1 2012 56
Early Clinical Stage Products, H1 2012 57
Discovery and Pre-Clinical Stage Products, H1 2012 58
Assessment by Monotherapy Products, H1 2012 302
Assessment by Combination Products, H1 2012 303
Assessment by Route of Administration, H1 2012 304
Assessment by Stage and Route of Administration, H1 2012 305
Assessment by Molecule Type, H1 2012 307
Assessment by Stage and Molecule Type, H1 2012 308